North East and North Cumbria
ICS Formulary
ICS Formulary
2 Cardiovascular system
02-12 Statins
MHRA Drug Safety Update (September 2023) Statins: very infrequent reports of myasthenia gravis
| Atorvastatin |
|
First Choice
|
10mg, 20mg, 40mg & 80mg tablets
Do not prescribe 30mg & 60mg tablets (see below) |
|
| Rosuvastatin |
|
Formulary
|
5mg, 10mg, 20mg & 40mg tablets May be used as an alternative to atorvastatin for primary or secondary prevention in line with NEELI guidance
Do not prescribe:
|
|
|
| Simvastatin |
|
Formulary
|
|
 MHRA Drug Safety Update (Dec 2014): Simvastatin: dose limitations with concomitant amlodipine or diltiazem |
|
|
| Atorvastatin 30mg & 60mg tablets |
|
Non Formulary
|
30mg & 60mg tablets For preferred preparations, see main formulary entry above |
|
| Rosuvastatin |
|
Non Formulary
|
Capsules: 5mg, 10mg, 20mg, 40mg Tablets: 15mg, 30mg
For preferred preparations, see main formulary entry above |
|
|
Links
- Academic Health Science Network (North East and North Cumbria) - Atrial Fibrilation
- MHRA Drug Safety Update (Dec 2010): Fibrates: first-line treatment not recommended
- MHRA Drug Safety Update (Dec 2010): Fibrates: first-line treatment not recommended
- MHRA Drug Safety Update (Dec 2014): Simvastatin: dose limitations with concomitant amlodipine or diltiazem
- MHRA Drug Safety Update (May 2014): Statins: benefits and risks
- NICE NG148: Acute kidney injury: prevention, detection and management
- NICE NG185: Acute coronary syndromes
- NICE NG191: COVID-19 rapid guideline: managing COVID-19
- NICE NG238: Cardiovascular disease: risk assessment and reduction, including lipid modification
- NICE TA 733 - Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia
- NICE TA1002 : Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over
- NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
- NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
- NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
- NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
- NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
- NICE TA694 - Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
- NICE TA694 - Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
- NICE TA805: Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides
- Northern England Evaluation and Lipid Intensification (NEELI) Guideline